BRVE (Braveheart Bio) ROCE %: -5.36% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BRVE Braveheart Bio Inc BRVE
8 GF Score
Price $31.93
View Full Analysis

What is Braveheart Bio ROCE %?

Braveheart Bio BRVE -2.72% 8 ROCE % is -5.36% as of Dec. 2025. GuruFocus rates BRVE with a GF Score™ of 8/100.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Braveheart Bio's annualized ROCE % for the quarter that ended in Dec. 2025 was -5.36%.

Braveheart Bio  (NAS:BRVE) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Braveheart Bio ROCE % Related Terms

Braveheart Bio ROCE % Historical Data

* Premium members only.

The historical data trend for Braveheart Bio's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Braveheart Bio ROCE % Chart

Braveheart Bio Annual Data
Trend Dec25
ROCE %
-5.36

Braveheart Bio Semi-Annual Data
Dec25
ROCE % -5.36
BRVE
8GF Score
Braveheart Bio Inc BRVE
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Braveheart Bio ROCE % Calculation

Braveheart Bio's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: . 20 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: . 20 )(A: Dec. 2025 )
=/( ( ( - ) + ( - ) )/ )
=/( (+)/ )
=/
= %

Braveheart Bio's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: . 20 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: . 20 )(Q: Dec. 2025 )
=/( ( ( - ) + ( - ) )/ )
=/( ( + )/ )
=/
= %

(1) Note: The EBIT data used here is one times the annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -5.36% mean?
Braveheart Bio (BRVE) has a ROCE % of -5.36% as of Dec. 2025.
Is Braveheart Bio's ROCE % too high?
Braveheart Bio's current ROCE % is -5.36%. Overall, Braveheart Bio has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Braveheart Bio's ROCE % compare to ?
Braveheart Bio's ROCE % of -5.36% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Braveheart Bio's current ROCE % is -5.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Braveheart Bio stock overvalued right now?
Braveheart Bio (BRVE) has a current ROCE % of -5.36%. The current ROCE % is -5.36%. Braveheart Bio's overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Braveheart Bio (BRVE), the current ROCE % is -5.36% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Braveheart Bio Business Description

Comparable Companies
Address One Letterman Drive, Suite A4-300, Building A, San Francisco, CA, USA, 94129
Braveheart Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics to treat hypertrophic cardiomyopathy (HCM) and other cardiovascular diseases. Its flagship product candidate, BHB-1893, is an oral small-molecule cardiac myosin inhibitor being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM).
8GF Score

Get the complete analysis for BRVE

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.93
Price